Drug Positivity in U.S. Workforce Rises to Nearly Highest Level in a Decade, Quest Diagnostics Analysis Finds

The Quest Diagnostics Drug Testing Index™ examines illicit drug use by America's workforce based on an analysis of de-identified results of more than 9.5 million urine, 900,000 oral fluid, and 200,000 hair laboratory-based tests performed nationally by the company for employers in 2015. The findings were unveiled today at the Substance Abuse Program Administrators Association (SAPAA) annual conference being held in Louisville, Kentucky.

Insights from the 2015 data show that the positivity rate for 9.5 million urine drug tests in the combined U.S. workforce increased to four percent, a relative change of 2.6 percent over the positivity rate in 2014 (4.0% versus 3.9%). The 2015 positivity rate reflects a relative increase of 14 percent over the 10-year low of 3.5 percent observed in both 2010 and 2011. The last year that the positivity rate for urine drug tests in the combined U.S. workforce was at or above four percent was 2005, when it reached 4.1 percent.

Another notable trend is the rising positivity rate for post-accident urine drug testing in both the general U.S. and federally-mandated, safety-sensitive workforces. Post-accident positivity increased 6.2 percent in 2015 when compared to 2014 (6.9% versus 6.5%) and increased 30 percent since 2011 (5.3%). In addition, post-accident positivity for the safety-sensitive workforce has risen 22 percent during a five-year time period (2.8% in 2015 versus 2.3% in 2011).

In oral fluid drug testing, the overall positivity rate increased 47 percent over the last three years in the general U.S. workforce to 9.1 percent in 2015 from 6.7 percent in 2013. The increase was largely driven by double-digit increases in marijuana positivity during this time period. In 2015, there was a 25 percent relative increase in marijuana detection as compared to 2014 (7.5% versus 6.0%). Slightly more than nine percent of oral fluid test results were positive for one or more drugs, suggesting that nearly one in eleven job applicants were unable to pass an oral fluid drug screen.

Among drug testing methods, overall positivity in the general U.S. workforce was highest in hair drug tests, at 10.3 percent in 2015, a seven percent increase over 2014 (9.6%) Because hair testing shows repetitive drug use as far back as 90 days, it can give a more complete drug-use history. By comparison, urine detects recent or new drug use, typically in one to three days, and oral fluid detects recent drug use in the previous 24-48 hours. In the general U.S. workforce, the rate of amphetamine, marijuana, and heroin detection increased annually for the past five years in urine testing. Amphetamine positivity increased 44 percent and marijuana positivity increased 26 percent since 2011; almost half (45%) of individuals in the general U.S. workforce with a positive drug test for any substance in 2015 showed evidence of marijuana use. Heroin positivity in that period, indicated by the presence of the 6-acetylmorphine marker (6-AM), increased 146 percent. Oxycodone positivity rate has declined annually since 2011, confirming previous research showing that opioid prescriptions have declined in 49 states since 2012.

"Our nationally representative analysis clearly shows that drug use by the American workforce is on the rise, and this trend extends to several different classes of drugs and categories of drug tests," said Barry Sample, Ph.D., senior director, science and technology, Quest Diagnostics Employer Solutions. "The 2015 findings related to post-accident testing results should also be of concern to employers, especially those with safety-sensitive employees."

"The DTI statistics for the last five years underscore the threat to employers – and employees – from drug abusers in our workplace. The numbers on hair testing – the methodology with the longest look-back and therefore a more telling measurement of regular use – show a 34-percent positive-rate increase for illegal drug use by the general workforce in the last five years," said Mark de Bernardo, executive director, Institute for a Drug-Free Workplace. "However, all the numbers for various testing methodologies confirm this disturbing trend and should provide a wake-up call to employers to do more to combat workplace substance abuse and to do it more effectively."

Among urine test results indicating drug use for federally-mandated, safety-sensitive employees, heroin positivity increased a relative 4.5 percent since 2014, and a relative 84 percent since 2011. In addition, positive test results for safety-sensitive workers showed a seven percent year-over-year increase in amphetamines (0.58 % in 2015 versus 0.54 % in 2014).

"This report shows a welcome decline in workplace drug test positives for certain prescription opiates but a disturbing increase in heroin positives. This rise in heroin should concern both policymakers and employers. Substance abuse is a safety risk for everyone. This new workplace evidence is an additional sign of the rising national heroin problem, this time in the workplace," said Robert DuPont, M.D., former director of the National Institute on Drug Abuse (NIDA).

About the Quest Diagnostics Drug Testing Index
The Quest Diagnostics Drug Testing Index (DTI) is an analysis of test results according to three categories of workers: federally mandated, safety-sensitive workers; the general workforce; and the combined U.S. workforce. Federally mandated, safety sensitive workers include pilots, bus and truck drivers, and workers in nuclear power plants, for whom routine drug testing is mandated by the U.S. Department of Transportation and the Nuclear Regulatory Commission. Quest Diagnostics has analyzed annual workplace drug testing data since 1988. The strengths of the Drug Testing Index analysis include its large, nationally representative sample size, longitudinal monitoring, a testing population that is generally reflective of the U.S. workforce and the quality of the company's drug testing services to confirm positive results. Limitations include analysis only of employers that perform drug testing with the company and a lack of exact cross-specimen comparisons due to variations in substances for which employers test.

The complete 2016 Quest Diagnostics Drug Testing Index can be found here. For more information about the Quest Diagnostics Drug Testing Index, including comprehensive data from the current report, visit www.QuestDiagnostics.com/DTI.

About Quest Diagnostics
Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 44,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

Drug Testing Index © 2001-2016 Quest Diagnostics Incorporated.

Quest, Quest Diagnostics, Athena Diagnostics and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics.

Contacts:

Wendy Bost, Quest Diagnostics (Media): 973-520-2800
Shawn Bevec, Quest Diagnostics (Investors): 973-520-2900

Photo - http://photos.prnewswire.com/prnh/20160914/407575
Photo - http://photos.prnewswire.com/prnh/20160914/407577-INFO
Photo - http://photos.prnewswire.com/prnh/20160914/407576-INFO
Logo - http://photos.prnewswire.com/prnh/20150422/200883LOGO

SOURCE Quest Diagnostics

Related Links

http://www.questdiagnostics.com